Gilead
NICE recommends Harvoni for hepatitis C
March 3, 2015Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir
NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
Merck puts HIV drug in shared patent pool
February 24, 2015Research and Development, Sales and Marketing AbbVie, Gilead, HIV, Merck, Raltegravir, Roche, isentress
Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …
Charity challenges Sovaldi patent
February 10, 2015Sales and Marketing Gilead, HCV, Médecins du Monde, sofosbuvir, sovaldi, world health organization
Doctors of the World (also known as Médecins du Monde) has filed an opposition to the patent for Gilead’s blockbuster …
Gilead expands UK presence with new London HQ
February 10, 2015Research and Development, Sales and Marketing Cambridge, Gilead, London, NICE, UK, johnson, medcity, sovaldi, uxbridge
Gilead is to create a new UK commercial secondary headquarters in central London doubling its UK workforce to 600 by …
Pharma adverse event FDA reports are inadequate
February 5, 2015Sales and Marketing FDA, Gilead, Solvaldi, US Institute for Safe Medication Practices, pharma, sofosbuvir
Reports of adverse drug events submitted to the FDA by pharma firms are often incomplete and lacking in detail, a …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
BMS wins FDA approval for HIV pill
January 30, 2015Sales and Marketing BMS, Bristol-Myers Squibb, FDA, Gilead, Reyataz, atazanavir, cobicistat), evotaz, tybost
Bristol-Myers Squibb has earned FDA approval for its HIV combination treatment Evotaz. The US drugs regulator gave BMS the go-ahead …
Gilead makes two senior promotions
January 30, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, andrew cheng
Gilead Sciences has promoted Dr Andrew Cheng to the position of executive vice president, HIV therapeutics and development operations, and …
New drug added to generic Sovaldi licensing
January 26, 2015Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi
Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …
Gilead and Strides partner in HIV
January 21, 2015Research and Development, Sales and Marketing Cipla, FDA, Gilead, HIV, Ranbaxy, Tenofovir Alafenamide, WHO, strides, taf
Gilead is partnering with India-based pharma firm Strides Arcolab in a licensing agreement to manufacture and distribute an HIV treatment …
NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
Gilead acquires Phenex liver disease drugs
January 7, 2015Research and Development, Sales and Marketing Farnesoid X Receptor, Gilead, liver, nafld, nash, phenex
Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …
Abbvie Hep C drug gains FDA approval
December 22, 2014Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …
Janssen launches HIV combination pill
December 17, 2014Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost
Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
